Summary
"An upcoming data readout for the phase 3 VISTA trial using Vicinium in NMIBC patients who don't respond to BCG therapy is expected by May 13, 2019.
Depending upon the primary and secondary endpoint data from the phase 3 VISTA trial, Sesen Bio expects to talk to the FDA for a registration strategy in 2019.
Sesen Bio has another phase 1 study that is treating patients with NMIBC. However, this time around, Vicinium is given in combination with AstraZeneca's Imfinzi.
Sesen Bio has cash and cash equivalents of $50.4 million as of December 31, 2018, and believes it has enough to fund operations into 2020.
Sesen Bio (NASDAQ:SESN) is gearing up for a major event in the coming weeks. That's because it will host a conference call to both release earnings and give an update on one of its late-stage studies using Vicinium to treat patients with bladder cancer. This will take place on May 13, 2019, at 8:00 a.m. EDT. It will be a major catalyst event, because it is the most advanced clinical product in its pipeline. I believe that the study should do pretty well for the population it is treating. There is no guarantee that the study will succeed, however. For that, I can point to the fact that there is a backup combination study that is targeting the very same patient population, in addition to several other programs as well."
